#Belgium #radiopharmaceuticals #Telix Pharmaceuticals #GMP-Grade #Seneffe

Telix Manufacturing Solutions Achieves a Significant Milestone in Belgium

In a groundbreaking achievement, Telix Pharmaceuticals Limited has announced the successful production of its first Good Manufacturing Practice (GMP)-grade commercial radiopharmaceutical doses at its Telix Manufacturing Solutions (TMS) facility located in Seneffe, Brussels South. This pivotal moment marks Telix's entry into the commercial radiopharmacy arena in Europe, allowing for the supply of advanced medical solutions to healthcare providers across the region.

A State-of-the-Art Facility

TMS Brussels South stands as one of Europe's largest radiopharmaceutical production sites, featuring nine GMP lines, clean rooms, a fully-equipped radiopharmacy, and two cyclotrons across a spacious 2,800 square meters. The facility is designed to facilitate the in-house production and distribution of radiopharmaceuticals, ensuring the highest standards of compliance and quality.

In a statement, Raphael Ortiz, the CEO of Telix International, expressed his enthusiasm for the facility's opening:

“We are excited to launch Telix's commercial radiopharmacy capability in Europe and demonstrate our ability to meet the needs of patients and partners.”

This new setup not only fulfills the growing demand for radiopharmaceuticals but also positions Telix as a significant player in the European market, enabling the company to offer GMP-grade products and radiolabelling services both locally and internationally.

Collaboration with Local Hospitals

The initial production has been delivered to the AIRC hospital collaboration in Charleroi, Belgium, which includes three hospitals: Grand Hopital de Charleroi, Clinique Notre-Dame de Grâce de Gosselies, and HUMANI. Dr. Ivan Duran Derijckere of AIRC emphasized the impact of this development, stating that the accreditation of TMS Brussels South will increase access to innovative medical supplies and improve patient outcomes:

“I would like to thank Telix for its leadership and continued investment in innovative products and services for patients with cancer.”

This collaboration signals a promising step forward in enhancing treatment options for cancer patients, further solidifying Telix's commitment to addressing significant unmet medical needs.

Benefits for the Region

Belgium's own Prof. Dr. Nadia Withofs, President of the Belgian Society of Nuclear Medicine (BELNUC), echoed this sentiment, praising the historical role of Belgium in nuclear medicine and expressing excitement over the establishment of GMP operations in the region.

“TMS Brussels South can now manufacture GMP-grade 'hot doses' that are ready for patients today.”

Furthermore, the facility's extensive research and development capabilities, especially its focus on the production of alpha-emitting isotopes, solidify its position as a vital hub for the manufacturing of both clinically and commercially significant radiopharmaceuticals in the future. With this technology and capability, Telix aims not only to produce immediate solutions but to pave the way for advances that contribute to long-term healthcare solutions.

The Road Ahead

Healthcare providers in Europe seeking information on ordering finished radiopharmaceuticals, active pharmaceutical ingredients, or other related services are encouraged to visit Radiopharma Store.

In conclusion, Telix's achievement in Belgium marks a significant enhancement in the landscape of radiopharmaceuticals, improving access to advanced cancer diagnostics and treatments for medical professionals and their patients. As Telix continues to innovate and expand its reach, the potential for future developments in therapy and diagnostics is promising. Through this initiative, Telix Pharmaceuticals not only reinforces its leadership role but also commits to improving the quality of life for patients dealing with cancer and other critical illnesses.